MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-Resistant Depression
Conditions
Treatment-Resistant Depression
Trial Timeline
Mar 13, 2023 → Nov 28, 2023
NCT ID
NCT05454410About MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection
MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection is a phase 2 stage product being developed by Novartis for Treatment-Resistant Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT05454410. Target conditions include Treatment-Resistant Depression.
What happened to similar drugs?
0 of 2 similar drugs in Treatment-Resistant Depression were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05454410 | Phase 2 | Completed |
Competing Products
6 competing products in Treatment-Resistant Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 35 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 29 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 39 |
| GH001 + Placebo | GH Research | Phase 2 | 29 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 25 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 37 |